Pradaxa Bleeding Deaths Spur FDA Concerns, European Label Changes

FDA is investigating reports that more patients are experiencing serious bleeding events after taking Boehringer Ingelheim GmbH’s Pradaxa (dabigatran) than anticipated based on clinical trial results.